Electromed (ELMD) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Electromed (ELMD) has outperformed Stereotaxis (STXS) over the past year, gaining 10.7% versus a loss of 68.9%. Over five years, ELMD leads with a +153.0% price change compared with -81.3% for STXS. Electromed is the larger company by market cap ($230.0 million vs $111.7 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELMD | STXS |
|---|---|---|
| Share price | $27.76 | $1.12 |
| Market cap | $230.05M | $111.73M |
| 1-day change | -0.14% | +0.45% |
| YTD return | -4.53% | -51.74% |
| 1-year return | +10.67% | -68.91% |
| 5-year return | +152.96% | -81.28% |
| P/E ratio (TTM) | 21.35 | — |
| Forward P/E | 45.51 | — |
| EPS (TTM) | $1.30 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.40 | $3.42 |
| 52-week low | $23.01 | $1.09 |
| Distance from 52-week high | -41.43% | -67.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +74.71% | +169.06% |
| Average volume | 104.86K | 808.41K |
| Shares outstanding | 8.29M | 100.20M |
| Employees | 195 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Electromed is about 2.1 times larger than Stereotaxis by market value ($230.05M vs $111.73M).
- ELMD has outperformed STXS by 79.6 percentage points over the past year.
About Electromed
ELMD stock →Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 195 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
ELMD vs STXS FAQ
Which is bigger, Electromed or Stereotaxis?
Electromed (ELMD) is larger, with a market capitalization of $230.05M compared with $111.73M for Stereotaxis (STXS).
Which stock has performed better over the past year, ELMD or STXS?
ELMD returned +10.67% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Electromed and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.